Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 SEK | -0.29% | -4.97% | -12.80% |
Mar. 27 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Mar. 11 | Enzymatica Obtains CE Marking for ColdZyme Mouth Spray | MT |
Sales 2024 * | 7.14M 77.19M | Sales 2025 * | 13.98M 151M | Capitalization | 55.1M 596M |
---|---|---|---|---|---|
Net income 2024 * | -3M -32.44M | Net income 2025 * | - 0 | EV / Sales 2024 * | 8 x |
Net Debt 2024 * | 2.01M 21.71M | Net cash position 2025 * | 2.05M 22.19M | EV / Sales 2025 * | 3.79 x |
P/E ratio 2024 * |
-18.7
x | P/E ratio 2025 * |
-39.7
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.72% |
1 day | -0.29% | ||
1 week | -4.97% | ||
Current month | +5.85% | ||
1 month | +8.86% | ||
3 months | -4.31% | ||
6 months | -0.29% | ||
Current year | -12.80% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 06-12-31 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 17-07-17 |
Director of Finance/CFO | 55 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 16-12-18 |
Director/Board Member | 56 | 16-02-14 | |
Director/Board Member | 57 | 21-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 3.44 | -0.29% | 23,983 |
24-04-22 | 3.45 | +1.77% | 66,198 |
24-04-19 | 3.39 | +0.30% | 47,573 |
24-04-18 | 3.38 | -2.59% | 86,653 |
24-04-17 | 3.47 | -2.25% | 69,420 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 10:09 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.80% | 54.79M | |
+27.92% | 659B | |
+27.68% | 557B | |
-4.59% | 359B | |
+16.38% | 322B | |
+9.39% | 297B | |
+6.30% | 215B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.58% | 149B |
- Stock Market
- Equities
- ENZY Stock